natgillin/translations-raw huggingface dataset:
Elevated product plasma levels may occur in patients with cholinesterase deficiency or under acetylcholinesterase inhibitors treatment since the product is inactivated at 90% by plasmatic esterases, see section 4.4 and 5.2. 
U bolesnika s nedostatkom kolinesteraze ili na terapiji inhibitorima acetilkolinesteraze može doći do povećane razine lijeka u plazmi jer se i do 90 % lijeka inaktivira plazmatskim esterazama, vidjeti dio 4.4 i 5.2. Zbog toga je potrebno primijeniti najnižu dozu koja omogućuje učinkovitu anesteziju.
• COMT-inhibitors to treat Parkinson's disease (such as entacapone or tolcapone); 
nortriptilin, maprotilin i protriptilin); • COMT inhibitore za liječenje Parkinsonove bolesti (npr. entakapon ili tolkapon);
7 MARKETING AUTHORISATION HOLDER [See Annex I - To be completed nationally] 
<[Vidjeti Prilog I. - ispunjava država članica]>
In embryotoxicity studies with articaine, no increase in the foetal mortality rate or malformations were observed at daily i.v. 
U ispitivanjima embriotoksičnosti s artikainom, nije uočeno povećanje stope fetalne smrtnosti ili malformacija kod dnevnih i.v. doza do 20 mg/kg u štakora i 12,5 mg/kg u zečeva.
Postganglionic adrenergic blocking agents (e.g., guanadrel, guanethidine, and rauwolfia alkaloids): Reduced doses of this medicinal product should be used under strict medical supervision with careful aspiration due to possible increase response to adrenergic vasoconstrictors: risk of hypertension and other cardiovascular effects. 
Treba koristiti manje doze ovog lijeka uz strogi medicinski nadzor i pažljivu aspiraciju zbog mogućeg pojačanog odgovora na adrenergičke vazokonstriktore: rizik od hipertenzije i drugih kardiovaskularnih učinaka.
• hot flush 
• navala vrućine
If you get any side effects, talk to your dentist, doctor or pharmacist. 
Ako primijetite bilo koju nuspojavu, potrebno je obavijestiti stomatologa, liječnika ili ljekarnika.
You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects, you can help provide more information on the safety of these medicines. 
Nuspojave možete prijaviti izravno putem nacionalnog sustava za prijavu nuspojava: navedenog u Dodatku V.
This medicine should not be used if the solution is cloudy or discoloured. 
Ovaj lijek ne smije se koristiti ako je otopina mutna ili je promijenila boju.
The lowest dose providing effective dental anaesthesia should be used. 
Potrebno je primijeniti najnižu dozu koja omogućuje učinkovitu dentalnu anesteziju.
• fatigue, weakness 
• umor, slabost • zimica
Sympathomimetic vasopressors (e.g., mainly cocaine but also amphetamines, phenylephrine, pseudoephedrine, oxymetazoline): 
Simpatomimetski vazopresori (npr. većinom kokain, no također i amfetamini, fenilefrin,
• severely overfunctioning thyroid (thyrotoxicosis); 
Vam je izrazito prekomjerno aktivna (tireotoksikoza);
Discard unused solution. 
Neiskorištenu otopinu baciti.
No adverse effects on fertility are anticipated at doses used for a dental procedure. 
Pri dozama korištenim za stomatološke zahvate ne očekuju se štetni učinci na plodnost.
3 PHARMACEUTICAL FORM Solution for injection. 
OBLIK I SADRŽAJ Otopina za injekciju.
• swelling of cheeks and local swelling 
• oticanje obraza i lokalni otok
Rare side effects: may affect up to 1 in 1,000 people: 
Ove nuspojave događaju se rijetko (mogu se javiti u do 1 na 1000 osoba).
Pack of 4 boxes containing glass cartridges 50 x 1.7 ml. 
Pakiranje od 4 kutije koje sadrže 50 staklenih uložaka od 1,7 ml.
• hoarseness 
• promuklost
Drugs causing arrhythmias (e.g., antiarrhythmics like digitalis, quinidine): Dose of administration of this medicinal product should be reduced due to the increased risk of arrhythmia when both adrenaline and digital glucosides are administered concomitantly to patients. 
Treba smanjiti dozu ovog lijeka zbog većeg rizika od aritmije kada se bolesnicima istodobno daju i adrenalin i glikozidi digitalisa.
• nervousness, anxiety 
Nervoza/anksioznost4
Patients with renal disease: The lowest dose leading to effective anaesthesia should be used. 
Bolesnici s bolešću bubrega Treba koristiti najnižu dozu koja omogućava učinkovitu anesteziju.
Dysesthesia (oral and perioral), including 
Hiperestezija Disestezija (oralna i perioralna),
Very rare 
Često
Box containing glass cartridges, self-aspirating 50 x 1.7 ml. 
Kutija koja sadrži 50 samoaspirirajućih staklenih uložaka od 1,7 ml.
As a result of the rapid drop in serum levels and rapid elimination, clinically relevant quantities of articaine are not found in breast milk. 
U majčinom mlijeku nisu pronađene klinički značajne količine artikaina zbog brzog pada razine u serumu i brze eliminacije.
[(Invented) name and associated names (see Annex I)} 40 mg/ml + 10 micrograms/ml, solution for injection] 
[{(Novoizumljeno) ime i pridružena imena (vidjeti Prilog I.)} 40 mg/ml + 10 mikrograma/ml, otopina za injekciju]
paralysis and paresis) Horner's syndrome (eyelid ptosis, enophthalmos, miosis). 
Hornerov sindrom (ptoza očnog kapka,
[(Invented) name and associated names (see Annex I)} 40 mg/ml + 5 micrograms/ml, solution for injection] 
[{(Novoizumljeno) ime i pridružena imena (vidjeti Prilog I.)} 40 mg/ml + 5 mikrograma/ml, otopina za injekciju]
• increased amount of blood in a part of the body leading to congestion of blood vessels 
• poremećaj usklađenosti srčanih otkucaja (poremećaji provođenja, atrioventrikularni blok) • povećana količina krvi u dijelu tijela koja dovodi do prepunjenosti krvnih žila
Patients with concomitant treatment with halogenated inhalation anaesthetics The lowest dose of the medicinal product leading to effective anaesthesia should be used (see section 4.5). 
Treba koristiti najnižu dozu lijeka koja omogućava učinkovitu anesteziju (vidjeti dio 4.5).
Elderly and Patients with renal disorders: 
Starije osobe i bolesnici s oštećenjem bubrežne funkcije
It is packed in single use glass cartridges sealed at the base by a mobile rubber plunger and at the top by a rubber seal kept in place by an aluminium cap. 
a na vrhu gumenim zatvaračem kojeg pridržava aluminijska kapica.
What you need to know before you are given X / Y Do not use X / Y if you suffer from any of the following conditions: 
Nemojte primjenjivati X/Y ako patite od bilo kojeg od niže navedenih stanja:
The lowest dose leading to efficient anaesthesia should be used in case of: 
Bolesnici s kardiovaskularnim poremećajima: Najniža doza koja omogućuje učinkovitu anesteziju treba se primijeniti u slučaju:
Patients with hepatic impairment 
Bolesnici s epilepsijom
• Patients with uncontrolled diabetes: This medicinal product should be used cautiously due to hyperglycemic effect of adrenaline. 
Ovaj lijek treba koristiti oprezno zbog hiperglikemijskog učinka adrenalina.
Injection site exfoliation / necrosis Fatigue, asthenia (weakness)/ Chills Not known Local swelling Feeling hot, Feeling cold c) Description of selected adverse reactions 
Eksfolijacija/nekroza na mjestu injiciranja Umor, astenija (slabost) / zimica Nepoznato Lokalno oticanje
Swelling of tongue, lip, gums Uncommon Stomatitis, glossitis Nausea, vomiting, diarrhoea 
Oticanje jezika, usana, desni Manje često Stomatitis, glositis
o 1 ml of X contains 40 mg of articaine hydrochloride and 5 micrograms of adrenaline (as adrenaline tartrate). 
o 1 ml X sadrži 40 mg artikainklorida i 5 mikrograma adrenalina (u obliku adrenalintartarata).
On account of its lower adrenaline content, the use of {(Invented) name and associated names (see Annex I)} 40 mg/ml + 5 micrograms/ml, solution for injection over {(Invented) name and associated names (see Annex I)} 40 mg/ml + 10 micrograms/ml, solution for injection should be preferred. 
Zbog nižeg sadržaja adrenalina, treba razmotriti primjenu {(Novoizumljeno) ime i pridružena imena (vidjeti Prilog I.)} 40 mg/ml + 5 mikrograma/ml otopine za injekciju umjesto {(Novoizumljeno) ime i pridružena imena (vidjeti Prilog I.)} 40 mg/ml + 10 mikrograma/ml otopine za injekciju.
1 ml of solution for injection contains 40 mg of articaine hydrochloride and 10 micrograms of adrenaline (as adrenaline tartrate). 
1 ml otopine za injekciju sadrži 40 mg artikainklorida i 10 mikrograma adrenalina (u obliku adrenalintartarata).
{(Invented) name and associated names (see Annex I)} 40 mg/ml + 5 micrograms/ml, solution for injection {(Invented) name and associated names (see Annex I)} 40 mg/ml + 10 micrograms/ml, solution for injection [See Annex I - To be completed nationally] 
{(Novoizumljeno) ime i pridružena imena (vidjeti Prilog I.)} 40 mg/ml + 5 mikrograma/ml, otopina za injekciju {(Novoizumljeno) ime i pridružena imena (vidjeti Prilog I.)} 40 mg/ml + 10 mikrograma/ml, otopina za injekciju [Vidjeti Prilog I. - ispunjava država članica]
• burning sensation 
• izrazita pospanost
1 ml of solution for injection contains 40 mg of articaine hydrochloride and 5 micrograms of adrenaline (as adrenaline tartrate). 
1 ml otopine za injekciju sadrži 40 mg artikainklorida i 5 mikrograma adrenalina (u obliku adrenalintartarata).
• swelling of tongue, lips and gums 
• nizak krvni tlak • oticanje jezika, usana i zubnog mesa
{(Invented) name and associated names (see Annex I)} 40 mg/ml + 5 micrograms/ml, solution for injection {(Invented) name and associated names (see Annex I)} 40 mg/ml + 10 micrograms/ml, solution for injection 
{(Novoizumljeno) ime i pridružena imena (vidjeti Prilog I.)} 40 mg/ml + 5 mikrograma/ml, otopina za injekciju {(Novoizumljeno) ime i pridružena imena (vidjeti Prilog I.)} 40 mg/ml + 10 mikrograma/ml, otopina za injekciju
What X / Y contains - The active substances are articaine hydrochloride and adrenaline tartrate. 
- Djelatne tvari su artikainklorid i adrenalintartarat.
Therefore, the lowest dose leading to effective anaesthesia should be used. 
Zbog toga treba koristiti najnižu dozu koja omogućava učinkovitu anesteziju.
The lowest dose leading to effective anaesthesia should be used. 
Treba koristiti najnižu dozu koja omogućava učinkovitu anesteziju.
• inflammation of the gums 
• otežano gutanje
Allodynia 
Glosodinija
Each cartridge of 1.7 ml of solution for injection contains 68 mg of articaine hydrochloride and 17 micrograms of adrenaline (as adrenaline tartrate). 
Svaki uložak od 1,7 ml otopine za injekciju sadrži 68 mg artikainklorida i 17 mikrograma adrenalina (u obliku adrenalintartarata).
• Patients with thyreotoxicosis: This medicinal product should be used cautiously due to the presence of adrenaline. 
Ovaj lijek treba koristiti oprezno zbog prisutnosti adrenalina.
Each cartridge of 1.7 ml contains 68 mg of articaine hydrochloride and 17 micrograms of adrenaline (as adrenaline tartrate). 
Jedan uložak od 1,7 ml sadrži 68 mg artikainklorida i 17 mikrograma adrenalina (u obliku adrenalintartarata).
NAME OF THE MEDICINAL PRODUCT {(Invented) name and associated names (see Annex I)} 40 mg/ml + 5 micrograms/ml, solution for injection articaine hydrochloride/adrenaline 
NAZIV LIJEKA {(Novoizumljeno) ime i pridružena imena (vidjeti Prilog I.)} 40 mg/ml + 5 mikrograma/ml, otopina za injekciju artikainklorid/adrenalin
NAME OF THE MEDICINAL PRODUCT {(Invented) name and associated names (see Annex I)} 40 mg/ml + 10 micrograms/ml, solution for injection articaine hydrochloride/adrenaline 
NAZIV LIJEKA {(Novoizumljeno) ime i pridružena imena (vidjeti Prilog I.)} 40 mg/ml + 10 mikrograma/ml, otopina za injekciju artikainklorid/adrenalin
Each cartridge of 1.7 ml contains 68 mg of articaine hydrochloride and 8.5 micrograms of adrenaline (as adrenaline tartrate). 
Jedan uložak od 1,7 ml sadrži 68 mg artikainklorida i 8,5 mikrograma adrenalina (u obliku adrenalintartarata).
Box containing glass cartridges 50 x 1.7 ml. 
Kutija koja sadrži 50 staklenih uložaka od 1,7 ml.
Uncommon side effects: may affect up to 1 in 100 people: 
Manje česte nuspojave: mogu se javiti u do 1 na 100 osoba: • osjećaj pečenja
MedDRA Sytem 
I DOHVATA
Each cartridge of 1.7 ml of solution for injection contains 68 mg of articaine hydrochloride and 8.5 micrograms of adrenaline (as adrenaline tartrate). 
Svaki uložak od 1,7 ml otopine za injekciju sadrži 68 mg artikainklorida i 8,5 mikrograma adrenalina (u obliku adrenalintartarata).
Enophthalmos 
Nuspojave
Halogenated volatile anaesthetics (e.g., halothane): 
inhibitori katekol-O-metiltransferaze (COMT) (npr. entakapon, tolkapon):
Uncommon Neck pain Rare 
Manje često Osjećaj pečenja
o Each cartridge of 1.7-ml of solution for injection of X contains 68 mg of articaine hydrochloride and 8.5 micrograms of adrenaline (as adrenaline tartrate). 
o Jedan uložak od 1,7 ml otopine za injekciju X sadrži 68 mg artikainklorida i 8,5 mikrograma adrenalina (u obliku adrenalintartarata).
The symptoms are dose-dependent and have progressive severity in the realm of neurological manifestations (restlessness, agitation, presyncope, syncope) followed by vascular (pallor (local, regional, general)), respiratory (apnoea (respiratory arrest), bradypnoea, tachypnoea, respiratory depression) and finally cardiac (cardiac arrest, myocardial depression) toxicity. 
sinkopa), praćeno vaskularnom (bljedilo (lokalno, regionalno, opće)), respiratornom (apneja
• abnormal rapid heartbeats; 
• nenormalno brze otkucaje srca;
The use of {(Invented) name and associated names (see Annex I)} 40 mg/ml + 5 micrograms/ml, solution for injection over {(Invented) name and associated names (see Annex I)} 40 mg/ ml + 10 micrograms/ml, solution for injection should be considered on account of its lower adrenaline content of 5 micrograms/ml in: 
Zbog niže doze adrenalina (5 mikrograma/ml), primjenu {(Novoizumljeno) ime i pridružena imena (vidjeti Prilog I.)} 40 mg/ml + 5 mikrograma/ml otopine za injekciju umjesto {(Novoizumljeno) ime i pridružena imena (vidjeti Prilog I.)} 40 mg/ml + 10 mikrograma/ml otopine za injekciju treba razmotriti u:
Frequency Adverse Reactions 
Krvožilni poremećaji Često
• exfoliation and ulceration of the gums 
• ljuštenje i vrijedovi zubnog mesa
Package size bottle (HDPE) 
Dasselta 5 mg Filmom obložena tableta Primjena kroz usta bočica (HDPE)
EU Number 
Broj (EU) Odobrenja Ime
Name Strength Pharmaceutical Form 
Doza Farmaceutski oblik Put primjene
ATCvet code: QJ01FA96. 
ATCvet kod: QJ01FA96.
Date of first authorisation: 6 May 2011. 
Datum prvog odobrenja: 6. svibnja 2011.
The mean terminal half-life is 4.4 days. 
Prosječno vrijeme poluživota je 4,4 dana.
Once opened, use within 28 days. 
Jednom otvoren, upotrijebiti unutar 28 dana.
Date of last renewal: 
Datum zadnjeg produženja:
Data were collected on zoonotic bacteria and commensals. 
Podaci su skupljeni na zoonotskim bakterijama i na komenzalima.
Do not store above 25 °C. 
Ne čuvati iznad 25 °C.
The effect is generally time-dependent. 
Učinak uglavnom ovisi o vremenu izlaganja.
Wash hands after use. 
Oprati ruke nakon primjene.
S: susceptible; I: intermediate; R: resistant 
S: jako osjetljivi; I: srednje osjetljivi; R: otporni
In very rare cases, individual shock reactions with a potentially fatal outcome might occur. 
U vrlo rijetkim slučajevima mogu se dogoditi individualne šok reakcije s potencijalno fatalnim ishodom.
If you notice any serious effects or other effects not mentioned in this package leaflet, please inform your veterinary surgeon. 
Ako primijetite bilo kakve ozbiljne učinke ili učinke koji nisu spomenuti u ovoj uputi, molimo da obavijestite svog veterinara.
The swellings are transient and will usually resolve within 7 to 16 days; in individual animals swellings may persist for 21 days. 
Otekline su prolazne i obično prođu između 7 i 16 dana; u pojedinih životinja otekline mogu trajati 21 dan.
Whenever possible, the veterinary medicinal product should only be used based on susceptibility testing. 
Kad god je moguće, veterinarsko medicinski proizvod treba koristiti samo na temelju testa osjetljivosti.
Do not use in automatically powered syringes which have no additional protection system. 
Ne koristiti automatsku špricu koja nema dodatni sustav zaštite.
85716 Unterschleissheim GERMANY 
85716 Unterschleissheim
The product has a long duration of action; however, the exact clinical effect duration after a single injection is unknown. 
Proizvod ima dugotrajno djelovanje, međutim točan klinički učinak trajanja nakon jedne injekcije je nepoznat.
There is cross resistance with other macrolides. 
Postoji križna rezistencija s drugim makrolidima.
The excipients listed in section 6.1 of the SPC are either allowed substances for which table 1 of the annex to Commission Regulation (EU) No 37/2010 indicates that no MRLs are required or are considered as not falling within the scope of Regulation (EC) No 470/2009 when used as in this veterinary medicinal product. 
Pomoćne tvari navedene u djelu 6.1 SPC-a su ili dozvoljene tvari za koje je tablici 1 dodatka Uredbe Komisije (EU) br. 37/2010 naznačeno da određivanje MRL nije nužno, odnosno smatra se da se na njih ne primjenjuju odredbe Uredbe (EK) br. 470/2009 kada se primjenjuju u tim veterinarskomedicinskim proizvodima.
Macrolides in general are bacteriostatic antibiotics but for certain pathogens can be bactericidal. 
Makrolidi su u osnovi bakteriostatski antibiotici, ali za određene patogene mogu biti baktericidni.
Mortality was observed at doses of 25 mg/kg body weight and higher. 
Smrtnost je primijećena u dozama od 25 mg/kg tjelesne mase i više.
These swellings resolved within 1 to 6 days. 
Otekline su nestale unutar 1 do 6 dana.
Once opened, use by: 
Jednom otvoren, upotrijebiti do:
Accidental injection is dangerous. 
Slučajno injiciranje je opasno.
The rubber stopper of the vial may be safely punctured up to 20 times. 
Gumeni čep bočice može se sigurno probušiti do 20 puta.
The injection volume should not exceed 5 ml per injection site. 
Volumen injekcije ne smije prelaziti 5 ml po mjestu uboda.
Injection should be given in a horizontal direction and a 90° angle to the body axis. 
Injekcija treba biti aplicirana u horizontalnom položaju i pod kutom od 90° u odnosu na tijelo.
EXP: Once opened, use by: 
EXP Jednom /otvoreno, upotrijebiti do:
The safety of the veterinary medicinal product has not been established during pregnancy or lactation. 
Neškodljivost veterinarsko medicinskog proizvoda nije utvrđena tijekom graviditeta ili laktacije.
Following metaphylactic use, approximately 86% of the healthy animals remained free of clinical signs of disease (as compared to approximately 65% of animals in the untreated control group). 
Slijedeći metafilaktičku upotrebu, približno 86% zdravih životinja su i dalje ostale bez kliničkih znakova bolesti (u odnosu na oko 65% životinja u netretiranoj kontrolnoj skupini).
Intervet International GmbH Feldstrasse 1 a 85716 Unterschleissheim GERMANY 
Intervet International GmbH Feldstrasse 1 a 85716 Unterschleissheim Njemačka
Swellings persisted for up to 3 days. 
Otekline su trajale do 3 dana.
Ask your veterinary surgeon/pharmacist how to dispose of medicines no longer required. 
Pitajte vašeg veterinara kako odlagati veterinarsko medicinske proizvode koji vam više nisu potrebni.
However, there was no evidence for any selective developmental or reproductive effects in any of the laboratory studies. 
Međutim, nije bilo dokaza za selektivnu pojavu razvojnih ili reproduktivnih učinaka u bilo kojem laboratorijskom ispitivanju.
Minimum inhibitory concentration (MIC) data for the target pathogens (wild type distribution) are presented in the table below. 
Minimumi inhibitorne koncentracije (MIC) za ciljne patogene (divlji tip distribucije) prikazani su u donjoj tablici.
Special attention should be paid to using the appropriate injection site and to use the appropriate needle size and length (adjusted to the size and weight of animal) according to Good Veterinary Practice. 
Obratiti posebnu pozornost na odgovarajuće mjesto ubrizgavanja i na korištenje odgovarajuće veličine i dužine igle (prilagođena veličini i težini životinje) prema dobroj veterinarskoj praksi.
Bovine respiratory disease 
Respiratorne bolesti svinja
5831 AN Boxmeer The NETHERLANDS 
5831 AN Boxmeer
Otherwise, the use of a multiple-dose syringe is recommended. 
Međutim, preporučuje se šprica za višestruke doze.
Do not administer intravenously. 
Ne primjenjivati intravenski.
MIC values for Salmonella were reported to be in the range of 4-16 µg/ml, and all strains were wild type. 
MIC vrijednosti za Salmonella su u rasponu od 4 - 16 µg/ml, a svi sojevi su divlji tip.
The active substance in Zuprevo is an allowed substance as described in table 1 of the annex to Commission Regulation (EU) No 37/2010: 
Djelatna tvar u Zuprevu je dozvoljena tvar kako je opisano u tablici 1 Priloga Uredbe Komisije(EU)
Tildipirosin is a 16-membered semi-synthetic macrolide antimicrobial agent. 
Tildopirosin je 16 - člani polusintetička makrolidna antimikrobna tvar.
For treatment of cattle over 450 kg body weight, divide the dose so that no more than 10 ml are injected at one site. 
Za liječenje goveda preko 450 kg tjelesne težine, podijeliti dozu tako da nije ubrizgano više od 10 ml na jedno mjesto.
A. MANUFACTURER RESPONSIBLE FOR BATCH RELEASE B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY OR USE C. STATEMENT OF THE MRLs 
PROIZVOĐAČ ODGOVORAN(I) ZA PUŠTANJE SERIJE U PROMET B. UVJETI ILI OGRANIČENJA U POGLEDU OPSKRBE I PRIMJENE C. IZVJEŠĆE O MRL
Three amine substituents at the macrocyclic lactone ring result in a tri-basic character of the molecule. 
Tri aminska supstituenta na makrocikličkom laktonskom prstenu rezultira trima glavnim osobinama molekule.
Carton Box 
Kartonska kutija
The mean terminal half-life is approximately 9 days. 
Prosječno vrijeme poluživota je 9 dana.
The mean total excretion of the total dose administered within 14 days was about 24% in urine and 40% in faeces. 
Prosječno izlučivanje ukupne doze primijenjene unutar 14 dana bilo je 24% urinom i 40% u fecesu.
The recommended injection site is the location just behind the ear at the highest point of the base of the ear, at the transition from bald to hairy skin. 
Preporučeno mjesto uboda je iza uha na najvišoj točci kod prijelaza golog na dlakavi dio kože.
4.7 Use during pregnancy and lactation or lay 
4.7 Primjena tijekom graviditeta, laktacije ili nesenja
Piglet, newborn Piglet, 3-4 weeks Growing 
Prase, okoćeno Odojak, 3 - 4 tjedna starosti Tovna prasad
It is recommended to treat animals in the early stages of the disease and to evaluate the response to treatment within 2 to 3 days after injection. 
Preporučuje se liječenje životinja u ranijim stadijima bolesti i ocjena odaziva na liječenje unutar 2 - 3 dana nakon injekcije.
Shelf life after first opening the container: 28 days. 
Rok valjanosti poslije prvog otvaranja spremnika: 28 dana.
In line with responsible use principles, metaphylactic use of Zuprevo is only indicated in severe outbreaks of SRD caused by the indicated pathogens. 
U skladu s načelima odgovornog korištenja, upotreba Zupreva u metafilaksi je indicirana samo kod izbijanja ozbiljnih DBS-a uzrokovanih navedenim uzročnicima.
SPECIAL STORAGE CONDITIONS Do not store above 25 °C. 
11. POSEBNI UVJETI ČUVANJA Ne čuvati iznad 25°C.
In very rare cases, anaphylactic reactions, with a potentially fatal outcome, might occur. 
U vrlo rijetkim slučajevima može se pojaviti anafilaktička reakcija s mogućim fatalnim ishodom.
They inhibit essential protein biosynthesis by virtue of their selective binding to bacterial ribosomal RNA and act by blocking the prolongation of the peptide chain. 
Inhibiraju osnovni protein biosinteze selektivnim vezanjem na bakterijske ribosomske RNA i djeluju blokirajući produljenje peptidnog lanca.
Do not use in case of hypersensitivity to macrolide antibiotics, citric acid monohydrate or propylene glycol. 
Ne primjenjivati u slučaju preosjetljivosti na makrolidnu skupinu antibiotika, limunsku kiselinu monohidrat ili propilen glikol.
In vitro binding of tildipirosin to porcine plasma proteins is limited with approximately 30 %. 
In vitro vezanje tildipirosina na proteine plazme u svinje je ograničeno na oko 30%.
B. bronchiseptica 
P. multocida B. bronchiseptica
PACKAGE SIZE 100 ml 
VELIČINA PAKOVANJA 100 ml
In case of accidental self-injection, seek medical advice immediately and show the package leaflet or the label to the physician. 
U slučaju samoinjiciranja, odmah potražiti medicinski savjet i pokazati liječniku upute ili etiketu.
TARGET SPECIES 
CILJNE VRSTE